The Association of Erythropoietin and Age-Related Macular Degeneration in Hemodialysis Patients: A Nationwide Population-Based Cohort Study

CNU IR > College of Smart Living > Dept. of Life and Health Science > Periodical Articles > Item 310902800/34607

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34607

Title:	The Association of Erythropoietin and Age-Related Macular Degeneration in Hemodialysis Patients: A Nationwide Population-Based Cohort Study
Authors:	Huang, Evelyn-Jou-Chen Sung, Fung-Chang Hung, Peir-Haur Muo, Chih-Hsin Wu, Meei-Maan Yeh, Chih-Ching
Contributors:	Taipei Medical University Taipei Medical University Hospital Taipei Medical University China Medical University Taiwan China Medical University Taiwan China Medical University Hospital - Taiwan Asia University Taiwan Department of Applied Life Science and Health, Chia Nan University of Pharmacy & Science China Medical University Taiwan Taipei Medical University Taipei Medical University Taipei Medical University China Medical University Taiwan Taipei Medical University Taipei Municipal WanFang Hospital
Keywords:	chronic kidney-disease stage renal-disease risk-factors eye disease protects retina anemia cells serum
Date:	2022
Issue Date:	2023-12-11 14:00:29 (UTC+8)
Publisher:	MDPI
Abstract:	This population-based retrospective cohort study investigated the effectiveness of erythropoietin (EPO) treatment in reducing the risk of age-related macular degeneration (AMD) in hemodialysis patients, using the National Health Insurance Research Data of Taiwan. From the database, we identified 147,318 end-stage renal disease (ESRD) patients on hemodialysis who had been diagnosed in 2000-2014 to establish the propensity-score-matched EPO user cohort and non-EPO user cohort with equal sample size of 15,992. By the end of 2016, the cumulative incidence of AMD in EPO users was about 3.29% lower than that in non-EPO users (Kaplan-Meier survival p < 0.0001). The risk of AMD was 43% lower in EPO users than in non-EPO users, with an adjusted hazard ratio (aHR) of 0.57 (95% confidence interval (CI) = 0.51-0.64) estimated in the multivariate Cox model. A significant negative dose-response relationship was identified between the EPO dosage and the risk of AMD (p < 0.0001). Another beneficial effect of EPO treatment was a reduced risk of both exudative AMD (aHR = 0.48, 95% CI = 0.40-0.61) and non-exudative AMD (aHR = 0.61, 95% CI = 0.53-0.69), also in similar dose-response relationships (p < 0.0001). Our findings suggest that EPO treatment for hemodialysis patients could reduce AMD risk in a dose-response relationship.
Relation:	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.23, n.17, 9634
Appears in Collections:	[Dept. of Life and Health Science] Periodical Articles

Files in This Item:

File	Description	Size	Format
ijms23179634.pdf		601Kb	Adobe PDF	117	View/Open
index.html		0Kb	HTML	219	View/Open

Loading...